# US 2010/0062444 A1 · Tle3 as a marker for chemotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0062444 A1
- Document ID: US20100062444A1
- Status: Published application
- Kind: A1
- Application number: 12/578,255
- Filed: 2009-10-13
- Published: 2010-03-11
- Earliest claimed: 2007-11-30
- Assignees: Applied Genomics, Inc.
- Inventors: Brian Z. Ring; Douglas T. Ross; Robert S. Seitz; Rodney A. Beck
- Web page: https://patentgrep.com/patent/US20100062444A1

## CPC

- G01N 33/57515: of the breast
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/66: Phosphorus compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57545: of the ovaries
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- G01N 2333/4703: Regulators; Modulating activity
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

## Claims

### Claim 1

A method for selecting a chemotherapy for a cancer patient comprising steps of:
providing a cancer sample from a breast, ovarian, or lung cancer patient;
determining whether TLE3 is expressed in the cancer sample; and
selecting a taxane or taxane derivative for the cancer patient based upon the presence of TLE3 expression in the cancer sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the step of determining comprises steps of:
providing a negative control sample;
detecting a level of TLE3 expression in the negative control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the negative control sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of determining comprises steps of:
providing a positive control sample;
detecting a level of TLE3 expression in the positive control sample;
detecting a level of TLE3 expression in the cancer sample; and
comparing the level of TLE3 expression in the cancer sample with the level of TLE3 expression in the positive control sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the step of determining comprises contacting the cancer sample with an interaction partner that binds a TLE3 polypeptide.

### Claim 5 (depends on 4)

The method of claim 4, wherein the interaction partner is an antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the step of determining comprises contacting the cancer sample with one or more primers that hybridize with a TLE3 polynucleotide.

### Claim 7 (depends on 6)

The method of claim 6, wherein the taxane is paclitaxel.

### Claim 8 (depends on 6)

The method of claim 6, wherein the taxane is docetaxel.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer patient has breast cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer patient has lung cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer patient has ovarian cancer.
